Closed-loop Insulin Delivery Systems in Pancreatic Diabetes (IADIASP)

Centre Hospitalier Sud Francilien

Status: Completed

Conditions: Secondary Pancreatic Diabetes

Treatments: Device: hybrid closed loop insulin delivery system

Study type: Observational

Funder types: Other

Identifiers

NCT06227650

2023/0057

Details and patient eligibility

About

The purpose of this study is to evaluate the metabolic and the safety outcomes in people living with pancreatic diabetes (pancreatitis or pancreatectomy-induced diabetes) and using a closed-loop insulin delivery systems ("artificial pancreas").

Full description

Secondary pancreatic diabetes is an unstable diabetes, due to deficiency in B cells which produce insulin, alpha cells which produce glucagon, and exorcrine insufficiency. Patients with secondary pancreatic diabetes are exposed to high glycemic variability and severe hypoglycemic episodes. Hybrid closed loop treatment has shown efficacy and safety for patients with type 1 diabetes and has the potential to improve the control of secondary pancreatic diabetes but has rarely been studied in this particular indication.

A retrospective observational cohort study in patients will be contucted suffering from secondary pancreatic diabetes in whom this device was implemented in order to observe metabolic and safety outcomes compared to the period before they were treated with hybrid closed-loop system.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient
• Presenting secondary pancreatic diabetes
• Treatment with insulin closed-loop delivery

Exclusion criteria

• Patient who objected to the use of data

Trial design

10 participants in 1 patient group

Group1

Description:

Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device

Treatment:

Device: hybrid closed loop insulin delivery system